INTRODUCTION

Oral leukoplakia (OL) is a relatively common premalignant lesion, which is presented as a white patch that cannot be scrapped off. Even though all leukoplakias do not transform into malignancies, Scully and Porter showed a 2.4% malignant transformation rate at 10 years which increased to 5% at 20 years period. This transformation involves many genetic alterations resulting in the inactivation of tumor suppressor genes and activation of proto-oncogenes by deletions, point mutations and gene amplification. Ninety percent of cancers occurring in oral cavity are oral squamous cell carcinomas (OSCCs). The development of oral cancer often involves multiple factors, some dependent on the genetic constitution or environmental factors and others on the lifestyle of the individual. A variety of cellular processes have been shown to be deregulated in cancer cells, for example, cell cycle control, apoptosis and telomerase stability. The cell cycle control may be disrupted due to abnormal functioning of growth factors, cyclin/cyclin dependent kinase (CDK) and decrease in negative regulatory factors owing to mutation in tumor suppressor genes. CDKs and cyclins control the switches for the transitions from one phase of cell cycle to the next phase. Cyclin dependent kinase-4 (CDK4) is a heterodimer protein, which is crucial for the progression of cell cycle in G1-S transition. This forms complexes with Cyclin D and hyperphosphorylates the target protein, i.e. retinoblastoma protein (Rb), resulting in its inactivation and liberation of E2F family of transcription factors. Thus, deregulation of Rb pathway clearly contributes to cancer formation. Over-expression of CDK4 occurs in lung cancers, sarcomas and melanomas. In addition, over-expression of CDK4 has been found in OSCC and in OSCC cell lines. Few studies have shown an increased expression of CDK4 in premalignant lesions with dysplasia and atypia after application of carcinogens like 4-nitroquinoline 1-oxide and 7,12-dimethybenzanthracene (DMBA).
suggesting possible role of CDK4 in carcinogenesis.\textsuperscript{[10,11]} Poomsawat\textit{ et al.} have found that CDK4 expression in normal mucosa was considerably lower than OL with dysplasia and OSCC suggesting that CDK4 might be implicated in the early event of carcinogenesis.\textsuperscript{[12]} Piboonniyom\textit{ et al.} have found the over-expression of CDK4 in OSCC and OSCC and the over-expression of CDK6 in only OSCC and suggested that CDK4 might be involved in the early event of carcinogenesis of OSCC and CDK6 might play a role later.\textsuperscript{[13]}

The purpose of this study was to determine and characterize the expression of CDK4 in OSCC and OL with different histological grades of dysplasia and to discuss possible role of CDK4 in tumor biogenesis.

**MATERIALS AND METHODS**

A total of 52 samples were obtained from patients consulting the Dental Clinics, Department of Surgical Oncology. This study was approved by the institutional committee on Human Rights and ethics related to Human experimentation. The tissue samples were fixed in 10\% buffered formalin and were processed using conventional histopathology techniques. Then, the samples were sectioned and stained with hematoxylin and eosin. The samples were then graded by two experienced histopathologists in a double-blind manner according to the criteria of an international symposium conclusions on oral white lesions.\textsuperscript{[14]} Our study included 30 cases of SCC (10 well differentiated, 10 moderately differentiated and 10 poorly differentiated), 15 cases of OL (5 mild dysplasia, 5 moderate dysplasias and 5 severe dysplasias) and 7 cases of normal mucosa used as controls. The cases were subjected to immunohistochemical staining for cell cycle protein CDK4 by using a slightly modified technique of labeled Streptavidin-Biotin immunohistochemical assay.\textsuperscript{[15]} Samples of normal oral mucosa were taken from buccal mucosa of healthy volunteers and patients who have undergone minor surgical procedures.

The antibodies and reagents used for immunohistochemical technique were obtained commercially from Sigma Aldrich Company (USA) and Progen Biotechnik (Germany). According to the manufacturer, the CDK4 antibody was raised in rabbits immunized with mouse CDK4 and reacted with CDK4 from mouse, rat or humans (Mouse, monoclonal and DCS 156 clone number).

**Immunohistochemical staining method**

Four micron thick sections were taken onto poly-l-lysine adhesive: coated slides, dried overnight at room temperature, de waxed in xylene and hydrated through descending grades of alcohol to phosphate buffered saline (PBS). For antigen retrieval, micro-sections were immersed in 10 M sodium citrate buffer and heated twice for 5 min each in microwave oven (800 W). Sections were allowed to cool down in citrate buffer and then washed in distilled water for 5 min followed by washing thoroughly in three changes of PBS. To block endogenous peroxidase activity, micro-sections were dipped in freshly prepared 3\% H\textsubscript{2}O\textsubscript{2} in 18\% methanol (V/V) in PBS for 10 min. Then sections were treated with 3\% bovine albumin serum at room temperature for 30 min, to block non-specific protein binding sites. Sections were then incubated with prediluted primary antibody (CDK4, diluted 1:40), at room temperature for 60 min in a humid chamber, later incubated with biotinylated secondary antibody (goat-antimouse IgG) diluted 1:100, at room temperature for 30 min. Further sections were incubated with streptavidin-peroxidase conjugate, for 20-30 min. For visualization, sections were incubated with 3-amino-9-ethyl carbazole (AEC) for 10-15 min and lightly counterstained by using Mayer’s hematoxylin, gently washed in running tap water and was mounted in an aqueous mounting media (Glycerol). Negative controls were carried out by omission of the primary antibody. Sections of an OSCC known to have nuclear staining for CDK4 were stained at the same time as positive controls for the antibody. All sections were processed under same conditions.

**Interpretation**

Assessment of antigen expressing cells was performed using light microscope at 10x and 40x magnifications. The criteria used to define CDK4 antigen positive cells were:

- Reddish brown staining in tumor cells, within the nucleus and cytoplasm
- Granular and homogenous staining within the tumor cells.

Sections of epithelial dysplasia and OSCC were evaluated for CDK4 expressing cells. In each case, four fields were selected randomly and evaluated for expression of CDK4 in the nucleus, cytoplasm and both the nucleus and the cytoplasm in the tumor cells invading the connective tissue and in the dysplastic epithelium in OSCC and OL, respectively. Slides were also evaluated for intensity of staining (dark and light) and appearance (granular and homogenous) of CDK4.

All the slides were evaluated by two qualified observers to minimize the subjective bias, the mean values of both the observers were subjected to Bonferonni ‘\textit{t}’ test to eliminate the inter-observer bias.

**Analysis**

Statistical analysis of the results was done using Bonferonni ‘\textit{t}’ test, Fishers \textit{F}-test (ANOVA) and Chi-square test. For these tests, \(P < 0.05\) and \(P < 0.001\) was considered to be significant and very highly significant, respectively.

**RESULTS AND OBSERVATIONS**

A total of 20 fields were observed in each of mild, moderate and severe epithelial dysplasias (histologically confirmed OLs). The intensity of the cells expressing CDK4 was evaluated and scored
as dark and light. When the appearance of CDK4 expressing cells was evaluated in different grades of dysplasias, it was found to be granular in all the fields of dysplasias. The staining intensity within the different grades of epithelial dysplasias was found to be very highly significant. On evaluating cells expressing CDK4 in the nucleus among different grades of dysplasias, a significant increase from mild to severe dysplasias was observed (Table 1, Figure 1). Cells expressing CDK4 in both the nucleus and cytoplasm showed a gradual increase from mild to severe dysplasias (Table 1). In different histological grades of OSCCs, there was a gradual decrease in nuclear CDK4 expressing tumor cells from well to poorly differentiated OSCCs (Table 2, Figure 2). Significant results were obtained showing a gradual increase in cytoplasmic CDK4 expressing cells from well to poorly differentiated OSCCs. Staining intensity of CDK4 expression was found to be gradually decreasing from well to poorly differentiated OSCCs and gradually increasing from mild to severe dysplasia (Table 3). However, the appearance of CDK4 expression was predominantly granular in well and moderately differentiated OSCCs and predominantly homogeneous in poorly differentiated OSCCs.

**DISCUSSION**

Tumor biogenesis is a complicated multistage process involving various genetic alterations. However, advances in cell cycle research have revealed a loss of G1 phase regulation, which is being regulated by sequential activation of cyclins and their catalytic partners like cyclin dependent kinase (CDKs). Further any disruption in this regulatory machinery can trigger an intramolecular interaction that may progressively block tumor suppressor gene products, which in turn might contribute to an uncontrolled cell proliferation. However, a number of studies have been reported on expression of CDKs in human malignancies indicating its oncogenic property.[12,16,17]

In our study, the immunoreactivity of CDK4 was observed in all 45 tissue samples of epithelial dysplasias and OSCCs, the expression being in both the nuclei and cytoplasm. These findings are in accordance with the study of Chen et al. on OSCC.[16] Further among the 10 cases of well differentiated SCC, most of the cancer cell lines revealed an increased expression of CDK4 protein.[16] This suggests genetic rearrangement and point mutation in the gene site of CDK4, i.e. 12q13, presumably by catalyzing the phosphorylation and inactivation of Rb proteins, allowing the release of E2F family of transcriptional factors and permitting the cells to pass through G1 to S phase check point with resultant cell proliferation. Though the tumor cells were more differentiated, the CDK4 protein expressing cells were abundant, probably indicating an accumulation of aberrant protein in these cells. Whereas in moderately and poorly differentiated SCC, though there was a constant down regulation in nuclear expression of CDK4 protein, there was a noticeable amount of accumulation of the protein in the cytoplasm. Probably here as the tumor cells are losing their differentiation, there may be either an over expression of certain inhibitory proteins like p16 or other inhibitory proteins, possibly through certain extrinsic or intrinsic factors which in turn may decrease functional phosphorylation of Rb protein and a decrease in CDK4 proteins. This knockout mechanism on CDK4 is in agreement with findings of An et al. on DMBA induced carcinogenesis.[13]
However, in the present study, as a component of nuclear protein, CDK4 should have been limited to the nuclei, but antigen was evident both in nucleus and cytoplasm in all grades of SCC. This feature was also observed in studies done by other researchers.\[^{19-21}\] Although the significance of cytoplasmic CDK4 expression is unclear, this might probably be due to a nonspecific reaction. This was also evidenced by Poomsawat et al. in their study on endometrial carcinomas who concluded it as having a different “functional status” or a “resting status” of CDK4.\[^{12}\]

A number of studies have suggested an inactivation of CDK inhibitors, involved in the development of epithelial dysplasias and oral SCCs.\[^{22-26}\] However, in the present study, a comparison of CDK4 staining showed a progressive increase in expression of this antigen from normal to different grades of epithelial dysplasia, being maximum in severe dysplasia and mainly localized to nuclei. This probably could be due to an amplification and translocation of 12q13, a stimulation of tumor biogenetic factors indicating an early event in progression from normal to dysplasia.\[^{12}\] Furthermore, in the present study all the 15 cases of epithelial dysplasias exhibited the habit of smoking and chewing tobacco. Probably, the carcinogens might have induced the amplification of CDK4 which is one of the genetic alteration, supporting the study of Sgambato et al. on carcinogen inducing rat mammary tumors.\[^{27}\]

In addition, to these observations in the current study, the staining intensity showed a progressive tendency for over-expression from normal to different grades of dysplasia and then in different grades of OSCC. However, among the dysplasias, severe dysplasias showed a dark staining ($P = 0.001$) [Table 3] compared to moderate and mild dysplasias and predominantly in the nuclei than the cytoplasm alone with a granular pattern. While in different grades of OSCC the staining intensity of CDK4 was greater in well differentiated SCC ($P = 0.001$) [Table 3] than in moderately and poorly differentiated SCC, with a heterotypic pattern and abundant nuclear staining. Further in well differentiated SCC, these positive cells were located mostly in the center of the epithelial islands than at the periphery [Figure 3]. While in poorly differentiated SCC the staining intensity was weak in majority of the cancer cell lines. One possible explanation for dark staining intensity could be decelerated catabolism of certain inhibitory proteins in the cancer cells which can further be related to tumor cell proliferation and later to metastasis of the tumor cells. The weak staining intensity in poorly differentiated SCC can be hypothesized as because of increased synthesis of inhibitory protein through unknown mechanism or might be due to mutant type of CDK4 protein. This finding further needs to be clarified, as the results of our study indicates a decline in cell proliferation protein, even though these tumor cells are proliferating and are becoming more undifferentiated which probably might be attributed to 12q13 gene alteration/aberration.

Various classifications have been proposed for classification of dysplasias. WHO system which was used in our study, (2005) is based on tissue architecture and cytology and it grades dysplasia in to hyperplasia (increased cell numbers without cellular atypia),
mild dysplasia (minimal architectural changes typically confined to the basal third of epithelium), moderate dysplasia (marked architectural changes seen in basal two-thirds of epithelium), severe dysplasia (marked architectural changes involving more than two-thirds of epithelium) and carcinoma in situ (severe form of epithelial dysplasia characterized by full thickness or almost full thickness cytological and architectural changes).\(^{[28,29]}\)

However, further studies on mutant type of CDK4 and its inhibitory proteins are essential to clarify the exact role of CDK4 in oral carcinogenesis.

**CONCLUSION**

The immunoreactivity and the staining intensity showed a progressive tendency for overexpression from normal to different grades of dysplasia (OLs) and in different histological grades of OSCC. However, the intensity of CDK4 was observed to be weak (light) in poorly differentiated OSCC, when compared to well- and moderately-differentiated OSCC. The molecular mechanisms underlying the observed down regulation of CDK4 in poorly differentiated OSCC is unclear. Further studies are essential by employing mutant types of CDK4 protein and various inhibitory proteins to understand the intricate function of CDK4 in the process of oral carcinogenesis.

**ACKNOWLEDGMENTS**

This study was supported by Manipal University. The authors would like to thank Mr. Kotian for statistical analysis, Mr. Shreepathy, Mrs. Nalini and Mr. Ganapathy for assisting in immunohistochemical procedures and staff of Department of Oral and Maxillofacial Pathology MCODS, Manipal, India for their support in this study.

**REFERENCES**

1. Scully C, Porter S. Orofacial disease: Update for the dental clinical team: 3 White lesions. Dent Update 1999;26:123-9.
2. Perez-Ordoñez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-53.
3. Boral AL, Dessain S, Chabner BA. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. Cancer Chemother Pharmacol 1998;42 Suppl: S3-21.
4. Kato J. Induction of S phase by G1 regulatory factors. Front Biosci 1999;4:D787-92.
5. Dohashi Y, Goto A, Fukayama M, Abe A, Ooi A. Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma. Int J Cancer 2004;110:532-41.
6. Kanoe H, Nakayama T, Murakami H, Hosaka T, Yamamoto H, Nakashima Y, et al. Amplification of the CDK4 gene in sarcomas: Tumor specificity and relationship with the RB gene mutation. Anticancer Res 1998;18:2317-21.
7. Wang YL, Uhara H, Yamazaki Y, Nikaido T, Saida T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 1996;134:269-75.
8. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P. Alterations of p53, pRb, cyclin D (1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 2000;36:334-9.
9. Patel V, Jakus J, Harris CM, Ensley JF, Robbins KC, Yeudall WA. Altered expression and activity of G1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck. Int J Cancer 1997;73:551-5.
10. Niwa S, Ueno S, Shirasu R. Alteration of pRb expression in the development of rat tongue carcinoma induced by 4-nitroquinoline 1-oxide. Oral Oncol 2001;37:579-85.
11. Miliani de Marval PL, Macias E, Coni CJ, Rodriguez-Puebla ML. Enhanced malignant tumorgenesis in Cdk4 transgenic mice. Oncogene 2004;23:1863-73.
12. Poomsawat S, Buajeeb W, Khovidhunkit SO, Punyasingh J. Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions. J Oral Pathol Med 2010;39:793-9.
13. Piboonniyom SO, Timmermann S, Hinds P, Münger K. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. Oral Oncol 2002;38:179-86.
14. Axéll T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco-related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International collaborative group on oral white lesions. J Oral Pathol Med 1996;25:49-54.
15. Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 1984;2:161-6.
16. Chen Q, Luo G, Li B, Samarayake LP. Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: A semi-quantitative immunohistochemical study. J Oral Pathol Med 1999;28:158-64.
17. Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4A in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250-6.
18. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999;154:113-8.
19. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997;74:57-63.
20. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-11.
21. Lu X, Chen S, Huang S. A study on methodology and the criteria for positive immunohistostaining of estrogen and progesterone receptors in paraffin embedded sections of breast cancer. Zhonghua Bing Li Xue Za Zhi 1996;25:329-31.
22. Dawson CD, Chang KW, Solt DB. MTS1 gene mutations in archival oral squamous cell carcinomas. J Oral Pathol Med 1996;25:541-6.
23. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Kato M, et al. Alterations of p16/CDKN2, p53 and ras genes in
oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996;25:232-8.
24. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
25. Sakata K. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. J Oral Pathol Med 1996;25:302-7.
26. Yeudall WA, Crawford RY, Ensley JF, Robbins KC. MTS1/CDK4 is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994;15:2683-6.
27. Sgambato A, Han EK, Zhang YJ, Moon RC, Santella RM, Weinstein IB. Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced rat mammary tumors. Carcinogenesis 1995;16:2193-8.
28. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. WHO Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Lyon: ARC Press; 2005.
29. Rastogi V, Puri N, Mishra S, Arora S, Kaur G, Yadav L. An insight to oral epithelial dysplasia. Int J Head Neck Surg 2013;4:74-82.